Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Daiichi Sankyo < Previous 1 2 Next > Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS Today 8:00 EST From Daiichi Sankyo Via Business Wire Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer November 12, 2024 From Daiichi Sankyo Via Business Wire ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product November 08, 2024 From Daiichi Sankyo Via Business Wire Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer October 30, 2024 From Daiichi Sankyo Via Business Wire ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy October 01, 2024 From Daiichi Sankyo Via Business Wire Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial September 23, 2024 From Daiichi Sankyo Via Business Wire Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial September 17, 2024 From Daiichi Sankyo Via Business Wire Tickers MRK DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors September 15, 2024 From Daiichi Sankyo Via Business Wire ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases September 13, 2024 From Daiichi Sankyo Via Business Wire Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial September 09, 2024 From Daiichi Sankyo Via Business Wire Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial September 08, 2024 From Daiichi Sankyo Via Business Wire Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial September 07, 2024 From Daiichi Sankyo Via Business Wire Tickers MRK Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO September 04, 2024 From Daiichi Sankyo Via Business Wire ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer August 19, 2024 From Daiichi Sankyo Via Business Wire Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 August 06, 2024 From Daiichi Sankyo Via Business Wire Tickers MRK IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer August 01, 2024 From Daiichi Sankyo Via Business Wire Tickers MRK Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer June 26, 2024 From Daiichi Sankyo Via Business Wire Tickers MRK Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial May 27, 2024 From Daiichi Sankyo Via Business Wire Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO May 21, 2024 From Daiichi Sankyo Via Business Wire ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial April 29, 2024 From Daiichi Sankyo Via Business Wire ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors April 05, 2024 From Daiichi Sankyo Via Business Wire Tickers AZN REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer April 03, 2024 From Daiichi Sankyo Via Business Wire Tickers MRK ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors January 29, 2024 From Daiichi Sankyo Via Business Wire Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer December 22, 2023 From Daiichi Sankyo Via Business Wire Tickers MRK Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes December 18, 2023 From Daiichi Sankyo Via Business Wire Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH December 01, 2023 From Daiichi Sankyo Via Business Wire ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial October 23, 2023 From Daiichi Sankyo Via Business Wire Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial October 23, 2023 From Daiichi Sankyo Via Business Wire Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial October 23, 2023 From Daiichi Sankyo Via Business Wire Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial October 22, 2023 From Daiichi Sankyo Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
